May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Patterns of Abnormal Fundus Autofluorescence in Advanced Atrophic AMD – Impact on Progression and Sample Size Calculation for Interventional Clinical Trials
Author Affiliations & Notes
  • M. Fleckenstein
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • A. Bindewald–Wittich
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • S. Schmitz–Valckenberg
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • H.P. N. Scholl
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • J. Dreyhaupt
    Institute for Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
  • U. Mansmann
    Institute for Biometry and Epidemiology (IBE), Ludwig–Maximilians–University, Munich, Germany
  • F.G. Holz
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • FAM study group
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Footnotes
    Commercial Relationships  M. Fleckenstein, None; A. Bindewald–Wittich, None; S. Schmitz–Valckenberg, None; H.P.N. Scholl, None; J. Dreyhaupt, None; U. Mansmann, None; F.G. Holz, None.
  • Footnotes
    Support  DFG grants: AMD SPP 1088, HO 1926/3–1; Heisenberg fellowship SCHO 734/2–1; EU FP6, Integrated Project
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5687. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Fleckenstein, A. Bindewald–Wittich, S. Schmitz–Valckenberg, H.P. N. Scholl, J. Dreyhaupt, U. Mansmann, F.G. Holz, FAM study group; Patterns of Abnormal Fundus Autofluorescence in Advanced Atrophic AMD – Impact on Progression and Sample Size Calculation for Interventional Clinical Trials . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5687.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We recently identified distinct patterns of abnormal FAF in the junctional zone of geographic atrophy (GA) (BJO 2005;89:874–8). Here we investigated the impact of such FAF phenotypes on GA progression rates. Based on these analyses we performed sample size calculations for interventional trials in this subset of AMD patients aiming at slowing GA progression and, thus, prevent additional visual loss and scotoma enlargement.

Methods: : In the prospective, multicenter natural history FAM study FAF images were recorded with a confocal scanning laser ophthalmoscope (cSLO) in 225 eyes from 147 patients over a median of 21 months. GA areas were quantified with digital image analysis and the impact of distinct patterns of abnormal FAF in the junctional zone of GA on progression rate was evaluated. Based on a linear regression model sample size was calculated for an interventional, randomized, double blind, parallel, clinical trial aimed to reduce speed of GA growth of 0,5 mm²/year at a significance level of α < 0.05 with a power of 80%.

Results: : Areas of GA showed a mean enlargement of 1.92±1.89 mm2/year. Eyes with diffuse and patchy FAF patterns had a significantly higher mean rate of progression (2.05±1.93 mm2/year) compared to eyes with no FAF abnormalities, focal or band patterns outside the GA (1.29±1.02 mm2/year; P=0.0009). In consideration of differential progression rates, a mean change of 1.85 mm² per year of the GA area with a total variability of 2.96 was determined. Sample size calculation based on these data gave186 patients per study arm.

Conclusions: : Based on cSLO FAF phenotyping we identified patterns of abnormal FAF in the junctional zone of GA associated with high and low progression rates of GA, respectively. Consideration of high–risk characteristics and, thus, prognostic factors is helpful to design a clinical trial in patients with GA. Based on our data we performed sample size calculations that considered ‘fast progressers’ and were thus able to reduce required sample sizes, which in turn would also increase the likelyhood to detect a therapeutic effect e.g. of a pharmocological agent to slow down rates of atrophy spread.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: natural history • imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×